News Hour

Rafiuzzaman Sifat

Md. Rafiuzzaman Sifat, a CSE graduate turned into journalist, works at News Hour as a staff reporter. He has many years of experience in featured writing in different Bangladeshi newspapers. He is an active blogger, story writer and social network activist. He published a book named 'Se Amar Gopon' inEkushe boi mela Dhaka 2016. Sifat got a BSc. from Ahsanullah University of Science & Technology, Bangladesh. He also works as an Engineer at Bangla Trac Communications Ltd. As an avid traveler and a gourmet food aficionado, he is active in publishing restaurant reviews and cutting-edge articles about culinary culture.

The new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that its new, dedicated high-volume testing immunoassay solution, the cobas e 801 module, is now available for countries accepting the CE Mark. As diagnostic laboratories evolve to...
Roche’s marketing applications for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of OCREVUS® (ocrelizumab) for the treatment of relapsing multiple sclerosis (RMS) and primary...
Promising data from next generation alk/ros1 inhibitor in advanced non-small cell lung cancer

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Pfizer Inc. (NYSE:PFE) announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer’s investigational, next-generation ALK/ROS1 tyrosine kinase inhibitor. The study showed clinical response in patients...
Data from phase 1b trial investigating utomilumab (a 4-1bb agonist) in combination with a checkpoint inhibitor

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Pfizer Inc. (NYSE:PFE) announced results from a Phase 1b trial of Pfizer’s investigational immunotherapy agent utomilumab (the proposed non-proprietary name for PF-05082566), a 4-1BB (also called CD137) agonist, in combination with pembrolizumab, a PD-1...
A mother’s mission to help prevent another life lost to menb

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: One moment Patti Wukovits was preparing for her daughter’s high school graduation, and the next moment she was watching her fight for her life for 9 days in the intensive care unit. In 2012,...
Advances body of evidence for tofacitinib citrate (xeljanz®) providing clinicians with additional information for the treatment of moderate to severe ra

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Pfizer Inc. (NYSE:PFE) announced that 23 abstracts, including research and analyses for tofacitinib citrate (XELJANZ®), will be featured at the upcoming European League Against Rheumatism (EULAR) Congress (June 8-11, London). The research being shared...
Fda advisory committees’ recommend alo-02 (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for approval

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted (9 to 6) in favor...
Pro golfer jim furyk teams up with pfizer to raise awareness for pneumococcal pneumonia and the importance of older adult vaccination

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: This Father’s Day, Jim Furyk will be thinking about more than just strategizing for the next Major as he joins Pfizer to encourage adults 65 and older to take responsibility for their health. On...
Two pivotal phase 3 studies for ertugliflozin, an investigational sglt-2 inhibitor, met primary endpoints

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2...
Final results from inotuzumab ozogamicin pivotal phase 3 study in adults with relapsed/refractory acute lymphoblastic leukemia

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Pfizer Inc. (NYSE:PFE) announced the publication of findings from the Phase 3 INO-VATE ALL study in the online issue of The New England Journal of Medicine. The study, also known as Study 1022, is an...

« Previous 1 … 92 93 94 95 96 … 109 Next »

Rafiuzzaman Sifat

The new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing

Roche’s marketing applications for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

Promising data from next generation alk/ros1 inhibitor in advanced non-small cell lung cancer

Data from phase 1b trial investigating utomilumab (a 4-1bb agonist) in combination with a checkpoint inhibitor

A mother’s mission to help prevent another life lost to menb

Advances body of evidence for tofacitinib citrate (xeljanz®) providing clinicians with additional information for the treatment of moderate to severe ra

Fda advisory committees’ recommend alo-02 (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for approval

Pro golfer jim furyk teams up with pfizer to raise awareness for pneumococcal pneumonia and the importance of older adult vaccination

Two pivotal phase 3 studies for ertugliflozin, an investigational sglt-2 inhibitor, met primary endpoints

Final results from inotuzumab ozogamicin pivotal phase 3 study in adults with relapsed/refractory acute lymphoblastic leukemia

Facebook

Twitter